Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
about
Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular EffectsAdaptive resistance to targeted therapies in cancerTargeted therapies in development for non-small cell lung cancerTherapeutic targeting of cancers with loss of PTEN function.PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataIdentification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokersPRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis.SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.Molecular pathology of lung cancer: current status and future directionsDevelopment of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerThe PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroupIncreased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancerThe EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells.Do oncogenic drivers exist in squamous cell carcinoma of the lung?Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell CarcinomaPIK3CA mutation analysis in Chinese patients with surgically resected cervical cancerPIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.Personalizing therapy in advanced non-small cell lung cancerA randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancerTargeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.Targeting genomic alterations in squamous cell lung cancer.Prognostic implications of PIK3CA amplification in curatively resected liposarcomamTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cellsPIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.Role of PTEN in basal cell derived lung carcinogenesis.Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.New targets in non-small cell lung cancer.Prognostic and predictive biomarkers in lung cancer. A review.Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).
P2860
Q26749011-C1C2D999-4AF7-42B6-8AC1-0F86ECEF9A01Q26849316-D852D0BE-EE00-4705-9193-62A035ECA1A5Q27022852-F9282165-660B-4FD3-A28F-735C02CFA393Q27852764-5BA281A1-34E5-4D4E-85C1-51C34FF81D5EQ28247338-86DC6F2C-0EAE-4C6F-B131-32387B35FFDBQ28383535-1CAC8DC9-9A0A-45D5-A14F-BC1A875499D3Q30008849-BE721DCE-B088-49CA-83C2-A123D0031B77Q33720115-52468008-7617-41BF-9414-320440676C0EQ34194997-D0C0C5A2-9157-45E8-8FAF-2FE91955DAB8Q34468621-A6C4EEFF-F0DA-490B-B625-98D9B50BEA2CQ34626967-AFBC7915-E957-4E80-9912-B7C6FC3DDA0EQ34995919-090A957D-5386-46B0-8E07-71D09BFB8B38Q35095308-A15A950C-93A2-4E8D-AF1E-757DAD61D4F8Q35149263-27F03E36-DB94-4EBB-85EC-AB9E959BF9B5Q35256618-3A0C71BF-3F57-4F88-9650-7490BBE7BAE0Q35725518-E0671674-8C4D-4A1F-A577-0D4645991F13Q35741494-D651CFEF-F6E3-4B30-86A7-F53BC53D9D6AQ35772123-1759C17A-1272-41AF-B019-6D3B8FA4B6B4Q35948290-E6889D94-8BFA-480C-BC9E-5DDE2289ABE5Q36049360-DE79FD48-762D-4FBC-87EE-ECF9FEBA5536Q36087843-C5A21CF0-B584-4A34-927C-9F4EBAD32109Q36274943-F3890DC0-9422-4FC1-87C8-B5180184388CQ36316643-EAFE52CB-B5EA-46C8-8F21-9D6523F1A76EQ36811453-62EA4C51-47F6-4666-828B-F981CFF92433Q36872593-04EE96F9-AA8B-469E-928A-49C20A82C91BQ36957609-231B036D-6868-4996-8C8E-25AF3A4CBCABQ37025086-A4949746-C45B-40C1-BBF9-9820A8E6903DQ37068767-EF9723E5-52D1-441C-86F9-C0A655B43296Q37269360-5EE68055-0180-48E9-8B4E-565ED57CE3A7Q37295372-5F9A8DD2-7129-482E-A9AD-C34524B1B1B4Q37327580-BC3D094C-A9B9-4559-84A2-F1CA82A3132AQ37529904-DB150926-2D30-43EF-A226-98A24131A453Q37698190-09E3BE3A-43FA-4BDF-942A-8627E4B106AFQ37703388-F260F4DC-B04B-4FA5-BF5D-4015C79F4671Q37721218-AE2C0784-1B09-4074-BD08-42FCCD320CB8Q37743107-4B3A34B8-8E96-499E-8789-5619D3107C29Q38114835-9F21D3B6-AC8F-469D-B70F-A8217CE45817Q38178187-A0CA5E18-77E7-45A0-B562-80F5C5605413Q38352879-F2463921-CB60-42F9-B6B4-51AE8AB870F2Q38358410-6B9C47B7-A885-4594-8115-C62CB556D012
P2860
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Phosphoinositide 3-kinase (PI3 ...... ung cancer preclinical models.
@en
Phosphoinositide 3-kinase
@nl
type
label
Phosphoinositide 3-kinase (PI3 ...... ung cancer preclinical models.
@en
Phosphoinositide 3-kinase
@nl
prefLabel
Phosphoinositide 3-kinase (PI3 ...... ung cancer preclinical models.
@en
Phosphoinositide 3-kinase
@nl
P2093
P1476
Phosphoinositide 3-kinase (PI3 ...... lung cancer preclinical models
@en
P2093
Ajay Pandita
Carol O'Brien
David S Shames
Deepak Sampath
Garret M Hampton
Hartmut Koeppen
Jane Fridlyand
Jill M Spoerke
Leanne Ross
P304
P356
10.1158/1078-0432.CCR-12-2347
P407
P577
2012-11-07T00:00:00Z